Aeterna Zentaris Inc
F:ET8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Iteris Inc
NASDAQ:ITI
|
US |
Aeterna Zentaris Inc
Total Current Liabilities
Aeterna Zentaris Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aeterna Zentaris Inc
F:ET8
|
Total Current Liabilities
$3.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-6%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Current Liabilities
CA$2.3m
|
CAGR 3-Years
54%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Current Liabilities
$93.7m
|
CAGR 3-Years
27%
|
CAGR 5-Years
24%
|
CAGR 10-Years
39%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Current Liabilities
$41.8m
|
CAGR 3-Years
23%
|
CAGR 5-Years
23%
|
CAGR 10-Years
31%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Current Liabilities
CA$5.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Current Liabilities
$32m
|
CAGR 3-Years
84%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Aeterna Zentaris Inc
Glance View
Aeterna Zentaris Inc. is a specialty biopharmaceutical company, which is engaged in commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The Company focuses on the commercialization of macimorelin in Asia and the rest of the world.
See Also
What is Aeterna Zentaris Inc's Total Current Liabilities?
Total Current Liabilities
3.6m
USD
Based on the financial report for Dec 31, 2025, Aeterna Zentaris Inc's Total Current Liabilities amounts to 3.6m USD.
What is Aeterna Zentaris Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
-6%
Over the last year, the Total Current Liabilities growth was -50%. The average annual Total Current Liabilities growth rates for Aeterna Zentaris Inc have been -20% over the past three years , -5% over the past five years , and -6% over the past ten years .
